“Based on the performance year-to-date, we now expect the new product portfolio to deliver roughly $3.5 billion for the full year 2023.”

In context

“g to Slide 13, let’s discuss our top line performance. Unless otherwise stated, all comparisons are made versus same period in 2022, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. Total company sales in the third quarter were $11 billion, driven by continued growth of our in-line and new product portfolio, offset by the expected decline in Revlimid sales. Let’s move to our new product portfolio on Slide 14. During the quarter, we delivered solid growth for the portfolio with $928 million in revenue. Growth was strong across the portfolio, but we have seen an impact of Abecma from both manufacturing site maintenance in June and from increased availability and usage of alternative BCM targeting therapies for multiple myeloma. Based on the performance year-to-date, we now expect the new product portfolio to deliver roughly $3.5 billion for the full year 2023. This is primarily due to the impacts of our cell therapy franchise, particularly Abecma. As Chris mentioned, we are laser focused on continuing to accelerate growth of our in-line and new product portfolio into the next year and beyond. Let’s discuss performance of our solid tumor products on Slide 15. Our flagship oncology product, Opdivo, continues to grow well with sales up 11% globally. In the U.S., Opdivo grew 9% primarily driven by demand. Sequentially, sales grew double digit driven by demand and a reversal of roughly $50 million of unfavorable buying patterns in the second quarter. Outside the U.S., third quarter revenues increased 15%, primarily driven by demand for indications such as lung and gastric cancer. This performance along with potential new launch opportunities in peri”